ClinConnect ClinConnect Logo
Search / Trial NCT05653973

Prenatal Aspirin and Postpartum Vascular Function

Launched by ANNA STANHEWICZ, PHD · Dec 15, 2022

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying how low-dose aspirin (LDA) affects blood vessel function in women who have experienced preeclampsia, a pregnancy condition that can lead to serious health issues later in life. Researchers want to understand how LDA might help improve the function of small blood vessels after pregnancy, especially since women with a history of preeclampsia are at a higher risk for heart problems. They will examine small blood vessels in the skin using a gentle technique, while also collecting blood samples to check for signs of inflammation.

To participate in this study, women must be between 18 and 62 years old and be between 12 weeks to 5 years postpartum. Eligible women include those who had normal pregnancies, with or without LDA, as well as those who had preeclampsia, with or without LDA usage. However, those currently using aspirin, with certain skin or health conditions, or who are pregnant cannot join. Participants can expect a simple and safe procedure to assess their blood vessel health and contribute to important research that could improve care for women after preeclampsia.

Gender

FEMALE

Eligibility criteria

  • Inclusion:
  • 18 years or older,
  • 12 weeks to 5 years postpartum
  • * and one of the following:
  • 1. women who had a normal pregnancy and did not use low does aspirin (LDA) during pregnancy,
  • 2. women who had a normal pregnancy and used LDA during pregnancy,
  • 3. women who had preeclampsia and did not use LDA during pregnancy,
  • 4. women who had preeclampsia and used LDA during pregnancy.
  • Exclusion:
  • current daily aspirin use,
  • skin diseases,
  • current tobacco use,
  • diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \< 60 mL/min/1.73m2,
  • statin or other cholesterol-lowering medication,
  • current antihypertensive medication,
  • history of hypertension prior to pregnancy,
  • history of gestational diabetes,
  • current pregnancy,
  • body mass index \<18.5 kg/m2,
  • allergy to materials used during the experiment.(e.g. latex),
  • known allergies to study drugs.

About Anna Stanhewicz, Phd

Dr. Anna Stanhewicz is a distinguished clinical trial sponsor with a robust background in biomedical research and a focus on innovative therapeutic interventions. Her expertise spans across cardiovascular health, metabolic disorders, and translational medicine, enabling her to effectively lead and oversee clinical studies aimed at advancing patient care. With a commitment to rigorous scientific methodology and ethical standards, Dr. Stanhewicz fosters collaborative environments that drive successful trial outcomes. Her leadership not only emphasizes the importance of patient safety and well-being but also aims to contribute valuable insights to the medical community.

Locations

Iowa City, Iowa, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials